Regenxbio

Regenxbio

Yahoo Finance • 2 days ago

Wednesday Sector Leaders: Computers, Biotechnology Stocks

In trading on Wednesday, computers shares were relative leaders, up on the day by about 5.6%. Leading the group were shares of AstroNova, up about 70.2% and shares of Nano Dimension Ltd (NNDM) up about 9.8% on the day. Also showing relat... Full story

Yahoo Finance • 30 days ago

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway

Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates. The company exited the quarter with $150.5 million in cash. Th... Full story

Yahoo Finance • last month

Regenxbio Shares Rise After Positive Duchenne Trial Results

medical research 10 ©Pixnio Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenne muscular dystrophy therapy, despite weak... Full story

Yahoo Finance • last month

Regenxbio slides after late-stage trial data for Duchenne therapy

[Duchenne muscular dystrophy genetic test] Hailshadow/iStock via Getty Images Following a brief trading halt, Regenxbio (RGNX [https://seekingalpha.com/symbol/RGNX]) lost ~18% in the premarket on Thursday after the company, alongside its... Full story

Yahoo Finance • last month

REGENXBIO Reports Positive Topline Data From Phase III AFFINITY DUCHENNE Trial Of RGX-202

(RTTNews) - REGENXBIO Inc. (RGNX) on Thursday announced positive topline and interim functional data from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, the company's gene therapy candidate for Duchenne Muscular Dystrophy. The... Full story

Yahoo Finance • 2 months ago

Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in REGENXBIO, Inc. (NASDAQ: RGNX) to contact the firm. Those who purchased RGNX securities between February 9, 2022 and January 2... Full story

Yahoo Finance • 2 months ago

REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX

NEW YORK, April 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story

Yahoo Finance • 2 months ago

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for viol... Full story

Yahoo Finance • 2 months ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

NEW YORK, April 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story

Yahoo Finance • 2 months ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

NEW YORK, April 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story

Yahoo Finance • 3 months ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PayPal Holdings, Inc. (N... Full story

Yahoo Finance • 3 months ago

ROSEN, A TOP RANKED INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive, (the “Clas... Full story

Yahoo Finance • 3 months ago

RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit — The Gross Law Firm

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class period listed are encouraged to con... Full story

Yahoo Finance • 3 months ago

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story

Yahoo Finance • 3 months ago

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story

Yahoo Finance • 3 months ago

Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors

LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 202... Full story

Yahoo Finance • 3 months ago

RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between Feb... Full story

Yahoo Finance • 3 months ago

ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story

Yahoo Finance • 3 months ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

NEW YORK, March 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story

Yahoo Finance • 3 months ago

Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience

This article first appeared on GuruFocus. Cash and Marketable Securities: $241 million as of December 31, 2025. Revenue: $170 million for the year ended December 31, 2025. R&D Expenses: $228 million for the year ended December 31, 2025. C... Full story